Cardiometabolic Health Congress

JANUARY 3, 2024

Food and Drug Administration (FDA) in 2021 as a once-weekly injection for chronic weight management in adults with obesity and at least one weight-related condition such as type 2 diabetes or hypertension. Among these options is semaglutide (Wegovy), a medication that has gained attention for its effectiveness in aiding weight loss efforts.

Obesity 97

Obesity Diabetes Blood Pressure BMI 97

Dr. Paddy Barrett

FEBRUARY 13, 2024

Even in diabetics of normal weight (BMI<27), weight loss can reverse diabetes 2. Be satiating Low in sugar In a Carbohydrate/Fat Balance that suits your preference and doesn’t drive your LDL cholesterol through the roof. Mostly, it is about weight loss, specifically visceral fat loss and the reversal of insulin resistance.

Diet 105

Diet Diabetes Exercise Kidney Disease 105

Dr. Paddy Barrett

AUGUST 16, 2024

Falling into the class of obesity with a BMI of greater than 30 makes this more likely, but so also does having excess visceral fat deposition with significant metabolic consequences at a BMI less than 30. The distinction here is the metabolic consequences of excess fat causing a health risk rather than focusing on the BMI cutoff.

Obesity 52

Obesity Blood Pressure Diet Exercise 52

Stroke Journal

JANUARY 30, 2025

Incident stroke (ischemic and hemorrhagic) was ascertained until the end of 2021 with adjudication by an expert panel. Cox regression was used to estimate the hazard ratio (HR) for incident stroke per doubling of EIC levels, and p-values were FDR corrected. Results:Among the 9,444 participants included, the mean age was 57 (5.7 SD), and 43.2%

Atherosclerosis 40

Atherosclerosis Stroke Strokes Atrial Fibrillation 40

Dr. Paddy Barrett

AUGUST 29, 2023

Share JUPITER In 2008 a landmark paper was published showing that in people without cardiovascular disease and relatively normal LDL-cholesterol (<3.4 Because of the increased risk, I am also quicker to introduce non-statin-based cholesterol-lowering agents such as ezetimibe, bempedoic acid, PCSK9 inhibitors or inclisiran when available.

Diabetes 52

Diabetes Risk Factors Heart Attack Heart attacks 52

DAIC

MARCH 8, 2024

The estimated relative risk reduction of MACE was 20% vs placebo (HR 0.80 [95% CI: 0.72, 0.90] p 1,2 The reduction of MACE with Wegovy was not impacted by age, sex, race, ethnicity, baseline BMI, or level of renal function impairment. 21, 25 May 2021. in patients randomized to Wegovy 2.4 mg and 36.4% of patients receiving placebo.

Obesity 111

Obesity Heart Disease Heart Attack Heart attacks 111